Please wait a minute...
Frontiers of Medicine

ISSN 2095-0217

ISSN 2095-0225(Online)

CN 11-5983/R

Postal Subscription Code 80-967

2018 Impact Factor: 1.847

Front. Med.    2010, Vol. 4 Issue (2) : 235-240     DOI: 10.1007/s11684-010-0002-0
Research articles |
Detection of maternal serum thromboxane B2 in different durations of pregnancy and prediction of preeclampsia
Geqing XIA MD1,Zehua WANG MD1,Li ZOU MD1,Chaoying WU MS1,Yu HU MD2,
1.Department of Obstetrics and Gynecology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China; 2.Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China;
Download: PDF(140 KB)  
Export: BibTeX | EndNote | Reference Manager | ProCite | RefWorks
Abstract  This study was aimed to detect maternal serum levels of thromboxane B2 (TXB2) in different durations of pregnancy and explore the predictive value of TXB2 for preeclampsia. By employing a prospective and double-blind study method, 180 pregnant women with previously normal blood pressures during their progestation were included in the study. Peripheral venous blood samples were obtained during 10+0–14+6 (period I), 20+0–24+6 (period II) and 30+0–34+6 (period III) weeks of gestation. Maternal serum levels of TXB2 were measured by enzyme-linked immunoassay. The pathogenetic condition and pregnancy outcomes of these cases were observed. (1) Among the 180 previously normotensive women, ten developed preeclampsia (case group; four severe and six mild preeclampsia). One hundred and seventy remained normal till the end of pregnancy (control group). (2) With development of pregnancy, the levels of maternal serum TXB2 in the 180 cases gradually ascended as seen through the Wilcoxon Signed Ranks Test. There was a statistical significance in maternal TXB2 levels between two different gestational stages (P<0.01). (3) The levels of maternal serum TXB2 were slightly higher in the case group than in the control group during period I of gestation, but the difference was not statistically significant (P>0.05); the levels of TXB2 were significantly higher in the case group than in the control group during periods II and III of gestation (both P<0.05). (3) The best cutoff points of maternal TXB2 were 3750 and 4400ng/mL during periods II and III of gestation by receiver operator characteristic (ROC) curve; and the sensitivity, specificity, positive predictive value, negative predictive value and odds radio of TXB2 in predicting preeclampsia were 80%, 69.5%, 13.3%, 98.33%, 9.11 and 90%, 68.82%, 13.84%, 99.13, 19.86, respectively. Higher levels of maternal serum TXB2 were detected a long time before clinical symptoms appeared. The maternal serum TXB2 after 20 weeks of gestation had predictive value, and the index after 30 weeks was superior to that prior to 30 weeks .
Keywords thromboxane B2      preeclampsia      
Issue Date: 05 June 2010
URL:     OR
Wu C S, Nohr E A, Bech B H, Vestergaard M, Catov J M, Olsen J. Health of childrenborn to mothers who had preeclampsia: a population-based cohort study. Am J Obstet Gynecol, 2009, 201(3): 269.e1–269.e10
Mathiesen E R, Johansen M, Kamper A L, Damm P. Hypertension during pregnancy. Ugeskr Laeger, 2009, 171(25): 2094–2097
Jelin A C, Cheng Y W, Shaffer B L, Kaimal A J, Little S E, Caughey A B. Early-onset preeclampsia and neonatal outcomes. J Matern Fetal Neonatal Med, 2009, 6: 1–5

doi: 10.1080/14767050903168416
Mills J L, DerSimonian R, Raymond E, Morrow J D, Roberts L J 2nd, Clemens J D, Hauth J C, Clemens J D, Hauth J C, Catalano P, Sibai B, Curet L B, Levine R J. Prostacyclin and thromboxane changes predating clinical onset ofpreeclampsia: a multicenter prospective study. JAMA, 1999, 282(4): 356–362

doi: 10.1001/jama.282.4.356
Spencer K, Yu C K, Cowans N J, Otigbah C, Nicolaides K H. Prediction of pregnancy complicationsby first-trimester maternal serum PAPP-A and free beta-hCG and withsecond-trimester uterine artery Doppler. Prenat Diagn, 2005, 25(10): 949–953

doi: 10.1002/pd.1251
Akolekar R, Etchegaray A, Zhou Y, Maiz N, Nicolaides K H. Maternal serum activin a at 11―13 weeksof gestation in hypertensive disorders of pregnancy. Fetal Diagn Ther, 2009, 25(3): 320–327

doi: 10.1159/000235878
ACOG Committee on ObstetricPractice. ACOG practice bulletin. Diagnosis and management of preeclampsia and eclampsia. Number 33, January 2002. AmericanCollege of Obstetricians and Gynecologists. Int J Gynaecol Obstet, 2002, 77(1): 67–75

doi: 10.1016/S0020-7292(02)80002-9
Yin S M, Xie S F, Nie D N, Li Y Q, Li Y Q, Li H M, Ma L P, Wang X J, Wu Y D, Feng J H. Effects of glycoprotein Ⅱb/Ⅲaantagonists and chloride channel blockers on platelet cytoplasmicfree calcium. Chin Med J (Engl), 2005, 118(23): 2020–2024
Wacker M J, Kosloski L M, Gilbert W J, Touchberry C D, Moore D S, Kelly J K, Brotto M A, Orr J A. Inhibition of thromboxane A2-induced arrhythmias and intracellular calciumchanges in cardiac myocytes by blockade of the IP3 pathway. J Pharmacol Exp Ther, 2009, 9 [Epub ahead of print]
Neppl R L, Lubomirov L T, Momotani K, Pfitzer G, Eto M, Somlyo A V. Thromboxane A2-inducedbi-directional regulation of cerebrl arterial tone. J Biol Chem, 2009, 284(10): 6348–6360

doi: 10.1074/jbc.M807040200
Sakariasse K S, Alberts P, Fontana P, Mann J, Bounameaux H, Sorensen A S. Effect of pharmaceutical interventions targeting thromboxane receptors andthromboxane synthase in cardiovascular and renal diseases. Future Cardiol, 2009, 5(5): 479–493

doi: 10.2217/fca.09.33
Malatyalioglu E, Adam B, Yanik F F, Kokcu A, Alvur M. Levels of stable metabolitesof prostacyclin and thromboxane A2 and their ratio in normotensiveand preeclamptic pregnant women during the antepartum and postpartumperiods. J Matern Fetal Med, 2000, 9(3): 173–177
Vainio M, Riutta A, Koivisto A M, Mäenpää J. Prostacyclin, thromboxaneA and the effect of low-dose ASA in pregnancies at high risk for hypertensivedisorders. Acta Obstet Gynecol Scand, 2004, 83(12): 1119–1123
Chavarria M E, Lara-Gonzalez L, Gonzalez-Gleason A, Garcia-Paleta Y, Vital-Reyes V S, Reyes A. Prostacyclin/thromboxane early changes in pregnancies that are complicatedby preeclampsia. Am J Obstet Gynecol, 2003, 188(4): 986–992

doi: 10.1067/mob.2003.203
Llinas M T, Alexander B T, Seedek M, Abram S R, Crell A. Thromboxanesynthesis during chronic reductions in uterine perfusion pressurein pregnant rats. Am J Hypertens, 2002, 15(9): 793–797

doi: 10.1016/S0895-7061(02)02975-8
Wasiluk A, Mantur M, Kemona H, Szczepanski M, Jasinska E, Milewski R. Thrombopoiesis in small for gestationalage newborns. Platelets, 2009, 14: 1–5

doi: 10.1080/09537100903207505
Al Kadi H, Nasrat H, Pipkin F B. A prospective, longitudinal study ofthe renin-angiotensin system, prostacyclin and thromboxane in thefirst trimester of normal human pregnancy: association with birthweight. Hum Reprod, 2005, 20(11): 3157–3162

doi: 10.1093/humrep/dei184
Drobny J. Metabolic syndrome and the risk of preeclampsia. Bratisl Lek Listy, 2009, 110(7): 401–403
Kho E M, McCowan L M, North R A, Roberts C T, Chan E, Black M A, Taylor R S, Dekker G A; SCOPE Consortium. Duration of sexualrelationship and its effect on preeclampsia and small for gestationalage perinatal outcome. J Reprod Immunol, 2009, 82(1): 66–73

doi: 10.1016/j.jri.2009.04.011
Farina A, Morano D, Arcelli D, De Sanctis P, Sekizawa A, Purwosunu Y, Zucchini C, Simonazzi G, Okai T, Rizzo N. Gene expressionin chorionic villous samples at 11 weeks of gestation in women whodevelop preeclampsia later in pregnancy: implications for screening. Prenat Diagn, 2009, 3 [Epub ahead of print]
Zahumensky J. Doppler flowmetry in preeclampsia. Bratisl Lek Listy, 2009, 110(7): 432–435
Mohammed N B, Kakal F. Uterine arteryDoppler ultrasonography in the first and second trimester for predictionof preeclampsia: implications for Pakistan. J Pak Med Assoc, 2008, 58(12): 718
Karina E, Tomasz P, Bilar M. Assessment of the female fetal DNA concentrationin the plasma of the pregnant women as preeclampsia indicator―preliminaryreport. Eur J Obstet Gynecol Reprod Biol, 2009, 146(2): 165–168

doi: 10.1016/j.ejogrb.2009.06.016
Delic R, Stefanovic M. Optimal laboratory panel for predicting preeclampsia. J Matern Fetal Neonatal Med, 2009, 29: 1–7

doi: 10.1080/14767050903156643
Zulfıkaroglu E, Isman F, Payaslı A, Kılıc S, Kucur M, Dan ısman N. Plasma visfatin levels in preeclamptic and normal pregnancies. Arch Gynecol Obstet, 2009, 29 [Epub ahead of print]
Apostolakis S, Shantsila E, Lip G Y. Angiopoietins and preeclampsia:new perspectives in the quest for markers. Am J Hypertens, 2009, 22(8): 820

doi: 10.1038/ajh.2009.108
No related articles found!
Full text